Talquetamab for Patients With Relapsed/Refractory MM

Results from the AQUILA trial led to the approval of subcutaneous daratumumab for patients with smoldering multiple myeloma at risk of developing the disease.

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

A real-world analysis of teclistamab, elranatamab, and talquetamab showed comparable outcomes in relapsed or refractory multiple myeloma.

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

Longer follow-up from the phase 3 MIDAS trial may be necessary to evaluate progression-free survival and overall survival.

Busulfan/melphalan elicited higher PFS among patients with ISS stage II or stage III disease, and melphalan-200 improved PFS in ISS stage I disease.